Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoma, T-Cell, Peripheral: early-phase trial registry
2 of 7 indexed Lymphoma, T-Cell, Peripheral trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 2 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Lymphoma, T-Cell, Peripheral: 7 US clinical trials tracked, 2 recruiting.
Lymphoma, T-Cell, Peripheral is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Rhizen Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition lymphoma-t-cell-peripheral
OPEN 2 | RECR 29% | LATE 1 | EARLY 5 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acromegaly (29% recruiting · 14 trials)
Lymphoma, T-Cell, Peripheral lists 2 open slots (29% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoma, T-Cell, Peripheral on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoma, T-Cell, Peripheral is recruiting below its size-band peers.
2 of 7 indexed trials (28.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lymphoma, T-Cell, Peripheral trials is spread across many organizations.
Rhizen Pharmaceuticals accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Lymphoma, T-Cell, Peripheral trials plan to enrol fewer than 100 people.
Median target enrolment is 57 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
Lymphoma, T-Cell, Peripheral research is mostly interventional.
6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Corvus Pharmaceuticals
NCT06561048
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
National Cancer Institute (NCI)
NCT07388563
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Seagen, a wholly owned subsidiary of Pfizer
NCT06254495
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
Ryan Wilcox
NCT03547700
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
Associazione Angela Serra per la ricerca sul cancro
NCT01142674
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
Rhizen Pharmaceuticals
NCT02567656
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Eisai
NCT00211185
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoma, T-Cell, Peripheral records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoma, T-Cell, Peripheral trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoma, T-Cell, Peripheral page
7 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Lymphoma, T-Cell, Peripheral trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Rhizen Pharmaceuticals sponsors the most Lymphoma, T-Cell, Peripheral trials on record, review their full trial history before evaluating a specific study. See Rhizen Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoma, T-Cell, Peripheral condition card totals 7 registered trials; most-linked intervention RP6530; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.